On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.

NetworkNewsBreaks – Interpace Diagnostics Group, Inc. (NASDAQ: IDXG) Named “Company of the Month” by G2 Intelligence; Shares Surge

Company: Interpace Diagnostics Group, Inc. (IDXG)
Category: News

Shares of Interpace Diagnostics Group’s (NASDAQ: IDXG) stock are up 4.8% after the company this morning said it has been selected by G2 Intelligence as the “Company of the Month for September 2017”. G2 Intelligence is the official publication of the Laboratory Industry Report and sponsor of the G2 War College, a laboratory industry conference. “We are honored that G2 Intelligence and the Laboratory Industry Report selected us as the Company of the Month.  We are extremely proud of the list of accomplishments highlighted in the article and very pleased of the recognition from such a well-respected publication,” Interpace Diagnostics president and chief executive officer Jack E. Stover stated in the news release.

To view the full press release, visit: http://nnw.fm/FN6Si

About Interpace Diagnostics Group, Inc.

Interpace Diagnostics is a fully integrated commercial company that provides clinically useful molecular diagnostic tests and pathology services for evaluating risk of cancer by leveraging the latest technology in personalized medicine for better patient diagnosis and management. The company currently has five commercialized molecular tests; PancraGEN for the diagnosis and prognosis of pancreatic cancer from pancreatic cysts; ThyGenX, for the diagnosis of thyroid cancer from thyroid nodules utilizing a next generation sequencing assay and ThyraMIR, for the diagnosis of thyroid cancer from thyroid nodules utilizing a proprietary gene expression assay; BarreGEN for evaluating the risk of progression to esophageal cancer in patients with Barrett’s esophagus; and now RespriDx™ for differentiating between  recurring lung tumors in the same organ vs. metastasis from another organ. Interpace Diagnostics’ mission is to provide personalized medicine through molecular diagnostics and innovation to advance patient care based on rigorous science. For more information, visit the company’s website at www.interpacediagnostics.com.

More from NetworkNewsBreaks

About NetworkNewsWire

NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

For more information please visit https://www.networknewswire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.networknewswire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Doge Coin

Dogecoin

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 212.418.1217